Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, 12-week, Randomised, Double-blind, Triple Dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) With Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease

NCT03478683 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03478683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03478683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, 12-week, Randomised, Double-blind, Triple Dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) With Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
June 25, 2018
Completion date
March 14, 2019
Enrollment
729 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive